

ESE Corporate Membership Brochure 2025

ESE: The voice for endocrinology

Endocrine conditions affect millions of people worldwide, spanning all ages, genders and nationalities. Our vision is to **shape the future of endocrinology to improve science, knowledge and health**. We represent a community of nearly **5000** individual members, along with more than **20 000** endocrine health care providers through our Council of Affiliated Societies (ECAS).

We work to:

- provide education for all career stages, and across all areas of endocrinology;
- develop clinical guidelines improving the standards of clinical care;
- organise the annual European Congress of Endocrinology (ECE), and
- support the patient community;
- advocate for and impact on **European health policies**, with specific focus on hormone health and disease.

Collaboration is critical in delivering our vision, and the ongoing efforts of our industry partners in research and development, as well as in making their products available around the world, support this vision. A strategic relationship with ESE through Corporate Membership provides your company with opportunities to connect with our membership through participation at events, share disease awareness materials through our various platforms, and to position yourself as a thought leader in the endocrine space.

2025: Strategic Collaborations

2025 will see the culmination of a number of ESE's collaborative projects, as well as the continuation of initiatives to which the support of our industry partners is instrumental.

In May, we will join with the European Society for Paediatric Endocrinology (ESPE) to deliver a joint Congress under the theme of **Connecting Endocrinology Across the Life Course**. This event promises to be a highlight of the endocrine calendar, bringing together over 6,500 endocrine specialists, with a global faculty discussing the latest science in paediatric and adult endocrinology, transition, and diseases covering the life span. Industry satellite symposia and the large exhibition and poster halls provide an unparalleled opportunity to share product information and research with the endocrine community.

The Congress will also be the launch point of the **EndoCompass Project**, which commenced in early 2023 with the objective of mapping the endocrinology research environment and identifying research needs and opportunities. Jointly led by ESE and ESPE, and with partners including the European Association for the Study of Obesity (EASO), Endo-ERN, the Growth Hormone Research Society (GRS) and many others, the project encompasses the spectrum of endocrine research priorities and promises to provide a clear vision around areas of high medical need and development opportunities.

ESE's focus on education will continue throughout 2025 and beyond, with the launch of the **ESE Learning**Management System (LMS) bringing together the many educational resources ESE has to offer, including

European Society of Endocrinology

Redwood House, Brotherswood Court, Great Park Road, Bradley Stoke, Bristol, BS32 4QW, UK info@ese-hormones.org www.ese-hormones.org



event recordings, disease awareness leaflets and supporting materials, for ESE's membership and event participants.

Additionally, two **independent medical education programmes**, in the areas of Rare Calcium, Phosphate and Bone Disorders (RCPBD), and Obesity, are in progress or due to commence in 2025, with the objective of identifying and addressing gaps in education in these areas. Further educational programmes are in discussion and engagement with these is subject to Corporate Membership.

Our established calendar of events will continue, including Clinical Update webinars and ESE Talks (from ESE's nurse community, European Women in Endocrinology (EuWIN), and jointly with ESPE and Endo-ERN in the rare disease space). The prestigious annual EuroPit meeting, plus events designed to bring together the early career community such as an in-person Post-Graduate Course in Romania, ESE Summer School and the ESE Young Endocrinologists and Scientists (EYES) Annual Meeting, provide a focus on the future. These in-person events offer a prime opportunity to network with the future Key Opinion Leaders in both clinical and basic endocrine practise.

Patients sit at the heart of all we do, and the popular **ESE Patient Forums** in the areas of hypoparathyroidism and adrenal will again take place in 2025. ESE's **Patient Advocacy Group (PAG) Affiliate Membership Scheme** will expand, from including only PAGs with a pan-European focus, to encompass country-specific PAGs. Through this scheme, ESE can support those PAGs with limited resources, to better serve their patient communities. PAGs will also, once again, be provided with space at the Congress to enhance the links between the patient community and clinicians.

We invite our Corporate Member companies to suggest additional areas and opportunities for similar programmes, events and initiatives, which will be considered by our committees.

Because Hormones Matter

With the launch of European Hormone Day in 2022, ESE brought the message of 'Because Hormones Matter' to the endocrine community. Over the past two years, the reach of this message has expanded and, following calls from national and partner societies and organisations, we are delighted to announce that 24 April will become the annual date of **World Hormone Day**. By taking a global approach, we can extend the message of the importance of good hormonal health to wider publics. In 2025 our focus is on raising **public awareness** of the importance of good hormone health, as well as improving national political engagement via our affiliated national societies and patient advocacy groups. This will be done not only through promoting WHD as a single day, but through engagement with other key disease-specific awareness days, weeks and months to ensure the message of Because Hormones Matter permeates across the year.

By providing support to World Hormone Day, and the broader message of Because Hormones Matter, companies enable us to deliver materials and activities to support this important message, such as communication toolkits to use with the public and policy makers, workshops to support organisations in planning their activities, public relations activities and a social media campaign, as well as a booth at the joint Congress of ESPE and ESE in Copenhagen in 2025.

We are requesting support from our corporate partners in an amount of €5,000, which will be acknowledged on related materials. In addition, supporting companies can:

• share patient-focused activities and materials via the ESE web pages, linked to World Hormone Day



- highlight (non-promotional) disease-specific resources under the banner of 'Because Hormones Matter' throughout the year, and in line with other national and global awareness days
- have social media posts around specific awareness days and activities reshared via the ESE and Because Hormones Matter accounts (Facebook, X, LinkedIn, Instagram)
- have the opportunity for a member/members of ESE's leadership to attend internal company meetings, to talk about the importance of endocrinology and how this relates to company activities.

A simple tick-box is included on the Corporate Membership application form to enable companies to opt in to provide support to this important initiative.

ESE Corporate Membership 2025

Benefits

Premium Corporate Membership	Corporate Member	Supporter		
Congress				
Acknowledgement on site at the 2025 Joint Congress of ESE and ESPE	Acknowledgement on site at the 2025 Joint Congress of ESE and ESPE	Acknowledgement on site at the 2025 Joint Congress of ESE and ESPE		
2 x Joint Congress full congress registrations	1 x Joint Congress full congress registration			
Membership				
3 x individual ESE memberships*	2 x individual ESE memberships*	1 x Individual ESE membership*		
Membership of ESE Industry				
Partnership Board (see below)				
Education				
NEW: Option to include company	NEW: Option to include company	NEW: Option to propose topics		
medical education resources on	medical education resources on	for 'Innovation in Endocrinology'		
ESE website	ESE website	webinars		
Acknowledgement				
Listing and logo on all ESE	Listing on all ESE quarterly	Listing on all ESE quarterly		
quarterly newsletter issues	newsletter issues	newsletter issues		
Listing and link to company page	Listing and link to company page	Listing and link to company page		
on ESE website	on ESE website	on ESE website		

^{*}nominated company representatives must meet the individual membership criteria as outlined on the ESE membership pages. Individual memberships are subject to approval by the ESE Executive Committee.

Fees

Please visit the ESE website to view the Corporate Membership Criteria

Membership Level	Cost* (per year)	World Hormone Day
		Supplement**
Premium Corporate Member	€30 000	€5,000



Corporate Member	€18 000	€5,000
Supporter	€6000	€5,000

ESE Corporate Membership is valid for one calendar year. We welcome multi-year agreements to aid in our planning.

NEW for 2025:

Industry education and updates

We recognise the importance of our Corporate Member and Supporter companies' expertise in endocrinology, with companies being key sources of updates on the latest in endocrine science and treatment. To maximise the accessibility of this information, from 2025, the ESE website will include a space dedicated to (non-branded) industry education and disease-awareness resources, such as links to company sites, documents, webinars and other related materials.

In addition, where company news such as clinical trial or product updates, events relevant to the treatment of endocrine diseases, or other activities arise, these can be shared with our membership via monthly and quarterly newsletters, as appropriate.

The ESE Industry Partnership Board (IPB)

<u>The IPB</u> gives a formal structure to the collaborative work between the Society and our Corporate Members at a strategic level, looking at ways in which society and industry can partner more closely to further advance the focus on and growth of the endocrine discipline in Europe.

Membership of the IPB is included as part of the Premium Corporate Membership benefits, with companies at this level demonstrating a long-term commitment to supporting the Society and endocrinology as a whole. The Board is jointly chaired by a nominated industry representative and the ESE Chief Executive Officer, with the ESE President and Chair of the ESE Education Committee also being board members.

For more information and to apply contact Natalie Dass: Natalie.Dass@ese-hormones.org

European Society of Endocrinology Company Limited by Guarantee.

Registered in England and Wales No.5540866. Registered Charity No. 1123492

Registered Office: Redwood House, Brotherswood Court, Great Park Road, Almondsbury Business Park, Bradley Stoke, Bristol, BS32 4QW, UK.

^{*}Prices are subject to VAT as applicable.

^{**}Optional



Thank you to our 2024 Corporate Partners:

Premium Corporate Members

HRA Pharma Rare Diseases (Now Esteve) Novo Nordisk Pfizer Recordati Rare Diseases

Corporate Members

Ascendis Pharma Inozyme Pharma Kyowa Kirin Neurocrine Biosciences/Diurnal Takeda Uni-Pharma

Supporters

Amolyt Pharma
BridgeBio
Camurus Pharmaceuticals
Crinetics Pharmaceuticals
Horizon Therapeutics
Ipsen